Article History
Received: 14 April 2020
Accepted: 27 April 2020
First Online: 13 May 2020
Competing interests
: CFC received advisory fees from Roche, Novartis, Boehringer, GSK, Astra Zeneca, Sanofi, Vifor and Mundipharma within the last 36 months. MK reports advisory fees from Novartis, Bayer, GSK, Mundipharma, Astra Zeneca and Boehringer Ingelheim. NAS has no competing interests.